• Episode 15: ESMO 2024 Commentary: Bladder Cancer

  • 2024/09/24
  • 再生時間: 28 分
  • ポッドキャスト

Episode 15: ESMO 2024 Commentary: Bladder Cancer

  • サマリー

  • In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment.

    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca


    This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

In the second episode of our ESMO Congress 2024 series, our hosts discuss both non-muscle invasive and muscle-invasive bladder cancer, along with other data that impacts the spectrum of urothelial cancer diagnosis and treatment.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca


This podcast has been made possible through unrestricted financial support by Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, J&J Innovative Medicine, Merck, Novartis, Pfizer, TerSera.

Episode 15: ESMO 2024 Commentary: Bladder Cancerに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。